Achieve Life Sciences ACHV Receipt Of SVB Convertible Term Loan Second Tranche

Receipt Of SVB Convertible Term Loan Second Tranche at other companies

Marriott Vacations WorldwideVAC

$354M+71.8%

Cogent Biosciences, Inc.COGT

$55.78M—

Eos Energy Enterprises, Inc.EOSE

$0-100%

LendingTreeTREE

$0-100%

MGN

MagniteMGNI

$0-100%

Dominion EnergyD

-$500M—

Other financials

Income statement

See full

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Balance sheet

See full

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Cash flow

See full

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Valuation

See full

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Returns & leverage

See full

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept achv:ReceiptOfSVBConvertibleTermLoanSecondTranche.

The official record: Achieve Life Sciences’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's receipt of svb convertible term loan second tranche.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Achieve Life Sciences's receipt of SVB convertible term loan second tranche?: Achieve Life Sciences (ACHV) reported receipt of SVB convertible term loan second tranche of $1.25M in Q4 2025.
What does receipt of SVB convertible term loan second tranche mean?: Cash inflows resulting from the drawdown of a specific tranche of a convertible term loan facility. This metric tracks the company's ability to access pre-negotiated debt financing to fund ongoing research and development or operational requirements.